Responses
Ovarian cancer
2022-RA-647-ESGO Real-word therapy and clinical and patient-reported outcomes in patients with newly diagnosed advanced ovarian cancer: first description of the SCOUT-1 study centers (NOGGO ov54, NCT04830709)
Compose a Response to This Article
Other responses
No responses have been published for this article.